DA-7503 / Dong-A - LARVOL DELTA

Drug Development. (PubMed, Alzheimers Dement) - "DA-7503 restores the impairments of memory and recognition, and ameliorates the aggregation and hyperphosphorylation of tau in transgenic mouse models of AD and other tauopathies. The inverse correlation between total Tau in CSF and DA-7503 exposure in plasma suggests that DA-7503 induces an increase of tau clearance from the brain and CSF tau may be explored as a biomarker in clinical development of DA-7503. Our findings indicate DA-7503 is a promising agent for the treatment of AD and primary tauopathies."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • CSF T-tau

DA-7503, a novel tau aggregation inhibitor, ameliorates tau pathology and reduces CSF tau in transgenic mouse models of Alzheimer’s disease and primary tauopathies (AAIC 2024) - "DA-7503 restores the impairments of memory and recognition, and ameliorates the aggregation and hyperphosphorylation of tau in transgenic mouse models of AD and other tauopathies. The inverse correlation between total Tau in CSF and DA-7503 exposure in plasma suggests that DA-7503 induces an increase of tau clearance from the brain and CSF tau may be explored as a biomarker in clinical development of DA-7503. Our findings indicate DA-7503 is a promising agent for the treatment of AD and primary tauopathies."

Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • CSF T-tau

A Study to Evaluate Safety, Tolerability, and PK of DA-7503 in Healthy Adult and Elderly Participants (clinicaltrials.gov) - P1 | N=72 | Not yet recruiting | Sponsor: Dong-A ST Co., Ltd.

New P1 trial